Alchemia Of Australia Finally Set To File For Synthetic Drug Generic
This article was originally published in PharmAsia News
Australia's Alchemia is looking for marketing partners now that it has overcome a three-year delay and filed for U.S. approval of its synthetic anti-clotting generic of GlaxoSmithKline's Arixtra (fondaparinux). Alchemia blamed its delay beyond the original 2006 filing target on the complexities involved in synthesizing the drug. The company expects FDA approval and marketing in the second half of this year, with Dr. Reddy's Laboratories already chosen to market the drug in India. (Click here for more
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.